ADHERE-S (NIS Brilique)

N/ACompletedNCT03444012

AstraZeneca269 enrolled

Overview

noninterventional study investigating persistence and adherence on ticagrelor in ACS patients in Serbia

Study Type

OBSERVATIONAL

Enrollment

269

Conditions

ACS (Acute Coronary Syndrome)

Interventions

ticagrelor 90 mgDRUG

persistence and adherence on ticagrelor in ACS patients

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * ≥ 18 years of age * diagnosed with ACS - STEMI or NSTEMI or unstable angina, invasively or non-invasively treated * Patients already on treatment with ticagrelor at least for 1 month and no longer than 3 months prior to study initiation. Enrolment in this study must not be trigger for ticagrelor initiation. * read and signed the Informed Consent Form Exclusion Criteria: Any contraindications as per approved SmPC of Brilique • Patients with life-threatening conditions which could disable patients to comply with scheduled visits and/or not able to fill in the patient questionnaires.

Locations (9)

CHC Bezanijska Kosa

Belgrade, Serbia

CHC Zemun

Belgrade, Serbia

CHC Zvezdara

Belgrade, Serbia

Clinical Center of Serbia

Belgrade, Serbia

Outcomes

Primary Outcomes

duration (number of days) on ticagrelor therapy in patients with acute coronary syndrome

Time frame: 1 year (12 months)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.